Perrigo gets FDA nod for generic Metrogel-Vaginal gel
Perrigo and its product development partner have received the Food and Drug Administration’s clearance for Metrogel-Vaginal (metronidazole vaginal gel 0.75%).
The product is the generic of Medicis Pharmaceuticals' Metrogel-Vaginal Gel.
Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter.
The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners.
"This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category. Our robust R&D pipeline remains focused on introducing more products that will create savings for patients and the U.S. healthcare system," Perrigo executive vice president and president Rx Pharmaceuticals, Sharon Kochan said.
MetroGel-Vaginal had a market value of about $100 million for the 12 months ending May 2019, according to IQVIA.
The product is the generic of Medicis Pharmaceuticals' Metrogel-Vaginal Gel.
Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter.
The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners.
"This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category. Our robust R&D pipeline remains focused on introducing more products that will create savings for patients and the U.S. healthcare system," Perrigo executive vice president and president Rx Pharmaceuticals, Sharon Kochan said.
MetroGel-Vaginal had a market value of about $100 million for the 12 months ending May 2019, according to IQVIA.